Literature DB >> 11714595

Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.

M Sato1, T Ishii, Y Kobayashi-Matsunaga, H Amada, K Taniguchi, N Miyata, K Kameo.   

Abstract

N-(4-Butyl-2-methylphenyl)-N'-hydroxyformamidine (HET0016) was evaluated as the first potent and selective inhibitor of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) synthase. The IC(50) value of HET0016 for the production of 20-HETE from arachidonic acid (AA) by human renal microsomes was 8.9+/-2.7 nM, with over 200 times the selectivity of xenobiotic-metabolizing cytochrome P450 enzymes. An examination of the structure-activity relationship revealed that the unsubstituted hydroxyformamidine moiety and the substituent at the para-position of the N-hydroxyformamidine moiety are necessary for the potent activity of HET0016.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714595     DOI: 10.1016/s0960-894x(01)00614-x

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  20-Hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries.

Authors:  Ludwig D Orozco; Huiling Liu; Eddie Perkins; Daryl A Johnson; Betty B Chen; Fan Fan; Rodney C Baker; Richard J Roman
Journal:  J Pharmacol Exp Ther       Date:  2013-05-08       Impact factor: 4.030

Review 2.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

3.  Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway.

Authors:  Irina Alecu; Alaa Othman; Anke Penno; Essa M Saied; Christoph Arenz; Arnold von Eckardstein; Thorsten Hornemann
Journal:  J Lipid Res       Date:  2016-11-21       Impact factor: 5.922

4.  Inhibitors of cytochrome P450 4A suppress angiogenic responses.

Authors:  Ping Chen; Meng Guo; Dana Wygle; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

5.  A new class of NO-donor pro-drugs triggered by γ-glutamyl transpeptidase with potential for reno-selective vasodilatation.

Authors:  Qingzhi Zhang; Agnieszka Kulczynska; David J Webb; Ian L Megson; Nigel P Botting
Journal:  Chem Commun (Camb)       Date:  2013-02-18       Impact factor: 6.222

6.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

Review 7.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

8.  Role of 20-HETE in the impaired myogenic and TGF responses of the Af-Art of Dahl salt-sensitive rats.

Authors:  Ying Ge; Sydney R Murphy; Fan Fan; Jan Michael Williams; John R Falck; Ruisheng Liu; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09

9.  Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles.

Authors:  Ying Ge; Sydney R Murphy; Yan Lu; John Falck; Ruisheng Liu; Richard J Roman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-14       Impact factor: 3.072

Review 10.  Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Authors:  Amanda L Johnson; Katheryne Z Edson; Rheem A Totah; Allan E Rettie
Journal:  Adv Pharmacol       Date:  2015-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.